Hillstream BioPharma (HILS) News Today $2.07 -0.03 (-1.43%) (As of 12/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Hill & Smith PLC HILSApril 17, 2024 | morningstar.comKiromic BioPharma Inc Ordinary Shares KRBPOctober 31, 2023 | morningstar.comHillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.September 22, 2023 | finance.yahoo.comDawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceSeptember 21, 2023 | finance.yahoo.comHillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic PruritisSeptember 11, 2023 | finance.yahoo.comHillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13September 8, 2023 | finance.yahoo.comHillstream – Drug Maker Licenses Critical New Technology In Fight Against CancerAugust 30, 2023 | benzinga.comNMTRQ 9 Meters Biopharma, Inc.August 25, 2023 | seekingalpha.comHillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023August 9, 2023 | finance.yahoo.comHillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215July 20, 2023 | finance.yahoo.comHillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and BiologicsJuly 10, 2023 | finance.yahoo.comHillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian CancersJuly 6, 2023 | finance.yahoo.comHILS - Hillstream BioPharma, Inc.June 9, 2023 | finance.yahoo.comHillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly AndersonMay 15, 2023 | finance.yahoo.comHillstream BioPharma, Inc.: Hillstream BioPharma Announces Closing of Public Offering of Common StockMay 4, 2023 | finanznachrichten.deHillstream BioPharma Announces Closing of Public Offering of Common StockMay 2, 2023 | finance.yahoo.comHillstream BioPharma to Present at Upcoming May 2023 Investor and Industry ConferencesMay 2, 2023 | finance.yahoo.comHillstream BioPharma Stock (NASDAQ:HILS), Short Interest ReportApril 29, 2023 | benzinga.comHillstream BioPharma, Inc.: Hillstream BioPharma Announces Proposed Public OfferingApril 28, 2023 | finanznachrichten.deHillstream BioPharma Shares Slide Premarket on Stock Offering >HILSApril 28, 2023 | marketwatch.comWhy Is Hillstream BioPharma (HILS) Stock Down 57% Today?April 28, 2023 | investorplace.comHillstream BioPharma, Inc.: Hillstream BioPharma Announces Pricing of Public OfferingApril 28, 2023 | finanznachrichten.deHillstream BioPharma Announces Pricing of Public OfferingApril 27, 2023 | finance.yahoo.comHillstream BioPharma Announces Proposed Public OfferingApril 27, 2023 | finance.yahoo.comHillstream BioPharma Selects OncoBay Clinical to Advance ClinicalApril 13, 2023 | tmcnet.comHillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer MechanismApril 13, 2023 | finance.yahoo.comHillstream BioPharma’s Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To GrowApril 12, 2023 | finance.yahoo.comHillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To GrowApril 11, 2023 | benzinga.comHillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical DataApril 10, 2023 | finance.yahoo.comHillstream BioPharma to Participate in Two Major Industry Conferences in April 2023March 28, 2023 | finance.yahoo.comHillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023February 28, 2023 | finance.yahoo.comHillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price RuleFebruary 15, 2023 | finance.yahoo.comHillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ETFebruary 13, 2023 | finance.yahoo.comHillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian CancerFebruary 13, 2023 | finance.yahoo.comHillstream Nearly Doubles on Test ResultsFebruary 10, 2023 | baystreet.caHillstream Soars on Promising HSB-1216 Data in Lung CancerFebruary 10, 2023 | msn.comIn a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis InducerFebruary 10, 2023 | finance.yahoo.comHillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & LeukemiasFebruary 8, 2023 | finance.yahoo.comHillstream BioPharma to Host Virtual R&D Day to Showcase its Emerging Immuno-oncology Pipeline Targeting Drug-Resistant CancersFebruary 6, 2023 | finance.yahoo.comWhy Are Hillstream BioPharma Shares Trading Over 100% Today?January 31, 2023 | finance.yahoo.comHillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant CancersJanuary 31, 2023 | finance.yahoo.comTrading was temporarily halted for "HILS" at 09:01 AM with a stated reason of "LULD pause."January 31, 2023 | marketbeat.comHillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023January 17, 2023 | finance.yahoo.comInsiders who purchased Hillstream BioPharma, Inc. (NASDAQ:HILS) stock last year recover some losses which currently stand at US$86kDecember 12, 2022 | finance.yahoo.comTrading was temporarily halted for "HILS" at 10:12 AM with a stated reason of "LULD pause."December 9, 2022 | marketbeat.comHillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated TargetsDecember 1, 2022 | finance.yahoo.comHillstream’s New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR SymposiumOctober 18, 2022 | finance.yahoo.comHillstream BioPharma, Inc. to Present at Upcoming Investor ConferencesOctober 6, 2022 | finance.yahoo.comHillstream BioPharma, Inc. (HILS)September 21, 2022 | finance.yahoo.comHillstream BioPharma to Participate in the Fierce...September 16, 2022 | benzinga.com Get Hillstream BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW HILS Media Mentions By Week HILS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HILS News Sentiment▼0.000.60▲Average Medical News Sentiment HILS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HILS Articles This Week▼00▲HILS Articles Average Week Get Hillstream BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MCRB News Today PBYI News Today PEPG News Today TELO News Today GALT News Today MNPR News Today IFRX News Today ATOS News Today APLT News Today ENTA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HILS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hillstream BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
